eXoZymes (NASDAQ: EXOZ) files updated Sept. 30, 2025 investor presentation

Rhea-AI Filing Summary

eXoZymes Inc. filed a current report to make public an updated Investor Presentation as of September 30, 2025. The company, which is listed on the Nasdaq Capital Market under the symbol EXOZ, is using this report to formally furnish the latest version of its presentation to investors and analysts.

The presentation is included as Exhibit 99.1 and is described as an Investor Presentation of eXoZymes Inc. as of September 30, 2025. No new financial results, transactions, or other specific operating updates are detailed in the text of this report itself.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0002010788 0002010788 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 30, 2025

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada		001-42204		83-4550057
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (626) 415-1488

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		EXOZ		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 — Other Events.

Attached is an updated Investor Presentation of eXoZymes Inc., a Nevada corporation, as of September 30, 2025.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibits		Description of Exhibit
99.1		Investor Presentation of eXoZymes Inc. as of September 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 3, 2025	EXOZYMES INC.
	By	/s/ Fouad Nawaz
		Fouad Nawaz,
		Vice President, Finance

FAQ

What did eXoZymes Inc. (EXOZ) disclose in this 8-K filing?

eXoZymes Inc. filed a current report to furnish an updated Investor Presentation as of September 30, 2025, making the materials publicly available as an exhibit.

Which exhibit contains the new eXoZymes (EXOZ) investor presentation?

The updated investor presentation of eXoZymes Inc. as of September 30, 2025 is filed as Exhibit 99.1 to this report.

Does this eXoZymes (EXOZ) 8-K include financial statements?

The report lists Item 9.01 for Financial Statements and Exhibits and identifies Exhibit 99.1 as an investor presentation and Exhibit 104 as the cover page interactive data file; no separate financial statements are described in the text.

On which exchange is eXoZymes Inc. (EXOZ) listed?

eXoZymes Inc.'s Common Stock is listed on the Nasdaq Capital Market under the trading symbol EXOZ.

What is the event date referenced in eXoZymes' 8-K?

The current report is dated with an earliest event date of September 30, 2025, which matches the date of the updated investor presentation.

Who signed this eXoZymes (EXOZ) 8-K on behalf of the company?

The report was signed on behalf of eXoZymes Inc. by Fouad Nawaz, who is identified as Vice President, Finance.